N 6-methyladenosine (m 6 A) is the most extensive studied RNA modification across various species, and the important effect of m 6 A modification in immune system has been revealed in distinct ...

Despite showing no meaningful benefit on lung function, Arcturus’ mRNA therapy ARCT-032 reduced mucus volume in patients with ...

The relatively new mRNA vaccines, which gained significant recognition during the coronavirus pandemic, are now also being ...

Therapeutics and Global Markets" report has been added to ResearchAndMarkets.com's offering.The global market for mRNA therapeutics was valued at $7.71 billion in 2025 and is forecast to remain stable ...

A breakthrough in our understanding of mRNA delivery systems in the body may allow for more direct treatments for pancreas-related diseases, including cancer and diabetes. A new UNLV study by a team ...

Researchers at Harvard Medical School and Brigham and Women's Hospital designed an ingestible capsule that delivers liquid mRNA to the intestines, producing gene expression and reducing inflammation ...

In the quest to design vaccines that better help the body's immune system fight disease, scientists are always looking for more tools for their arsenal. The strong antibody responses generated by ...

A KAIST research team led by Professor Won Do Heo (Department of Biological Sciences) has developed an optogenetic platform, RELISR (REversible LIght-induced Store and Release), that enables precise ...

Arcturus Therapeutics Holdings recently saw its consensus analyst price target lowered from $69.89 to $65.88, reflecting a modest dialing back of expectations about its future share value. This ...

On October 22, 2025, Arcturus Therapeutics Holdings announced interim Phase 2 clinical results for ARCT-032, its investigational inhaled mRNA therapy for cystic fibrosis, sharing details on mucus ...